目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT
6.1. Overview
6.2. Antibodies
6.2.1. Primary antibodies
6.2.2. Secondary antibodies
6.3. Reagents
6.3.1. Histological Stains
6.3.2. Blocking Sera and Reagents
6.3.3. Chromogenic Substrates
6.3.4. Fixation Reagents
6.3.5. Organic Solvents
6.3.6. Proteolytic Enzymes
6.3.7. Diluents
6.3.8. Other Reagents (antigen retrieval solutions, stabilizers, controls, and mounting solutions)
6.4. Equipment
6.4.1. Slide-staining Systems
6.4.2. Tissue Processing Systems
6.4.3. Slide Scanners
6.4.4. Other Equipment (automated cover slippers, visualization equipment, microtomes, paraffin dispensers, slide labelers, and tissue microarrays)
6.5. Kits
6.5.1. IHC Kits for Human tissue
6.5.2. IHC Kits for Animal tissue

7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION
7.1. Overview
7.2. Diagnostic applications
7.2.1. Cancer
7.2.2. Infectious diseases
7.2.3. Autoimmune diseases
7.2.4. Nephrological diseases
7.2.5. Neurological diseases
7.2.6. Other diseases (ophthalmic, cardiovascular, dermatological, and dental diseases)
7.3. Research applications
7.3.1. Drug Development and Testing
7.3.2. Other research applications (stem cell research and developmental biology)
7.4. Forensic applications

8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY END-USER
8.1. Overview
8.2. Hospitals & Diagnostic Laboratories
8.3. Academic & Research Institutes
8.4. Other end users (CROs, pharma & biopharma companies, and forensic laboratories)

9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America

10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Immunohistochemistry Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Immunohistochemistry Market,
10.7. Key Developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger &Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income,2023
10.8.2. Major Players R&D Expenditure.2023

11. COMPANY PROFILES
11.1. F. Hoffmann-LA-Roche AG (Switzerland)
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Danaher Corporation (US),
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Agilent Technologies Inc. (US),
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Merck KGAA (Germany).
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Bio-Rad Laboratories Inc. (US),
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Eagle Biosciences Inc. (US),
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Biocare Medical LLC. (US),
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Elabscience Biotechnology Inc. (China)
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Bio-Genex Laboratories (US)
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Diagnostic Biosystem (US)
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Histo-Line Laboratories (Italy),
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Rockland Immunochemicals Inc. (US)
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Products Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Genemed Biotechnologies Inc. (US),
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Products Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Candoor Bioscience GMBH (Germany),
11.14.1. Company Overview
11.14.2. Financial Overview
11.14.3. Products Offered
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. Bio-Techne Corporation (US)
11.15.1. Company Overview
11.15.2. Financial Overview
11.15.3. Products Offered
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
11.16. Abcam PLC (UK).
11.16.1. Company Overview
11.16.2. Financial Overview
11.16.3. Products Offered
11.16.4. Key Developments
11.16.5. SWOT Analysis
11.16.6. Key Strategies
11.17. Becton, Dickinson and Company (US),
11.17.1. Company Overview
11.17.2. Financial Overview
11.17.3. Products Offered
11.17.4. Key Developments
11.17.5. SWOT Analysis
11.17.6. Key Strategies
11.18. Perkinelmer Inc. (US),
11.18.1. Company Overview
11.18.2. Financial Overview
11.18.3. Products Offered
11.18.4. Key Developments
11.18.5. SWOT Analysis
11.18.6. Key Strategies
11.19. Takara Bio, Inc. (Japan),
11.19.1. Company Overview
11.19.2. Financial Overview
11.19.3. Products Offered
11.19.4. Key Developments
11.19.5. SWOT Analysis
11.19.6. Key Strategies
11.20. Thermo Fisher Scientific Inc. (US),
11.20.1. Company Overview
11.20.2. Financial Overview
11.20.3. Products Offered
11.20.4. Key Developments
11.20.5. SWOT Analysis
11.20.6. Key Strategies
11.21. PHC Holdings Corporation (Japan),
11.21.1. Company Overview
11.21.2. Financial Overview
11.21.3. Products Offered
11.21.4. Key Developments
11.21.5. SWOT Analysis
11.21.6. Key Strategies
11.22. Cell Signaling Technology Inc. (US),
11.22.1. Company Overview
11.22.2. Financial Overview
11.22.3. Products Offered
11.22.4. Key Developments
11.22.5. SWOT Analysis
11.22.6. Key Strategies
11.23. Bio SB Inc. (US),
11.23.1. Company Overview
11.23.2. Financial Overview
11.23.3. Products Offered
11.23.4. Key Developments
11.23.5. SWOT Analysis
11.23.6. Key Strategies
11.24. Miltenyi Biotech (Germany),
11.24.1. Company Overview
11.24.2. Financial Overview
11.24.3. Products Offered
11.24.4. Key Developments
11.24.5. SWOT Analysis
11.24.6. Key Strategies
11.25. Sakura finetek Japan Co., Ltd. (Japan),
11.25.1. Company Overview
11.25.2. Financial Overview
11.25.3. Products Offered
11.25.4. Key Developments
11.25.5. SWOT Analysis
11.25.6. Key Strategies
11.26. Enzo Biochem, Inc. (US)
11.26.1. Company Overview
11.26.2. Financial Overview
11.26.3. Products Offered
11.26.4. Key Developments
11.26.5. SWOT Analysis
11.26.6. Key Strategies
11.27. Origene Technologies Inc. (US).
11.27.1. Company Overview
11.27.2. Financial Overview
11.27.3. Products Offered
11.27.4. Key Developments
11.27.5. SWOT Analysis
11.27.6. Key Strategies

12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, ESTIMATES &FORECAST, 2019-2032(USD BILLION)
TABLE 3 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 9 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 10 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 11 US: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 12 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 13 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 14 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,2019-2032 (USD BILLION)
TABLE 5 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 10 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 11 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 12 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 16 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 17 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 18 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 28 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 29 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 30 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 31 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 32 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 33 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END-USER, 2019-2032 (USD BILLION)

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL IMMUNOHISTOCHEMISTRY MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL IMMUNOHISTOCHEMISTRY MARKET
FIGURE 4 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY PRODUCT, 2023
FIGURE 5 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY APPLICATION, 2023
FIGURE 6 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY END-USER, 2023
FIGURE 7 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: IMMUNOHISTOCHEMISTRY MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL IMMUNOHISTOCHEMISTRY MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 F. HOFFMANN-LA-ROCHE AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 F. HOFFMANN-LA-ROCHE AG (SWITZERLAND): SWOT ANALYSIS
FIGURE 15 DANAHER CORPORATION (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 DANAHER CORPORATION (US): SWOT ANALYSIS
FIGURE 17 AGILENT TECHNOLOGIES INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 AGILENT TECHNOLOGIES INC. (US): SWOT ANALYSIS
FIGURE 19 MERCK KGAA (GERMANY).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 MERCK KGAA (GERMANY).: SWOT ANALYSIS
FIGURE 21 BIO-RAD LABORATORIES INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 BIO-RAD LABORATORIES INC. (US): SWOT ANALYSIS
FIGURE 23 EAGLE BIOSCIENCES INC. (US), FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 EAGLE BIOSCIENCES INC. (US): SWOT ANALYSIS
FIGURE 25 BIOCARE MEDICAL LLC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 BIOCARE MEDICAL LLC. (US): SWOT ANALYSIS
FIGURE 27 ELABSCIENCE BIOTECHNOLOGY INC. (CHINA): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 ELABSCIENCE BIOTECHNOLOGY INC. (CHINA): SWOT ANALYSIS
FIGURE 29 BIO-GENEX LABORATORIES (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 BIO-GENEX LABORATORIES (US): SWOT ANALYSIS
FIGURE 31 DIAGNOSTIC BIOSYSTEM (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 DIAGNOSTIC BIOSYSTEM (US): SWOT ANALYSIS
FIGURE 33 HISTO-LINE LABORATORIES (ITALY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 HISTO-LINE LABORATORIES (ITALY): SWOT ANALYSIS
FIGURE 35 ROCKLAND IMMUNOCHEMICALS INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 ROCKLAND IMMUNOCHEMICALS INC. (US): SWOT ANALYSIS
FIGURE 37 GENEMED BIOTECHNOLOGIES INC. (US), FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 GENEMED BIOTECHNOLOGIES INC. (US), SWOT ANALYSIS
FIGURE 39 CANDOOR BIOSCIENCE GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 CANDOOR BIOSCIENCE GMBH (GERMANY): SWOT ANALYSIS
FIGURE 41 BIO-TECHNE CORPORATION (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 BIO-TECHNE CORPORATION (US): SWOT ANALYSIS
FIGURE 43 ABCAM PLC (UK).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 ABCAM PLC (UK).: SWOT ANALYSIS
FIGURE 45 BECTON, DICKINSON AND COMPANY (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 46 BECTON, DICKINSON AND COMPANY (US): SWOT ANALYSIS
FIGURE 47 PERKINELMER INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 48 PERKINELMER INC. (US): SWOT ANALYSIS
FIGURE 49 TAKARA BIO, INC. (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 50 TAKARA BIO, INC. (JAPAN): SWOT ANALYSIS
FIGURE 51 THERMO FISHER SCIENTIFIC INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 52 THERMO FISHER SCIENTIFIC INC. (US): SWOT ANALYSIS
FIGURE 53 PHC HOLDINGS CORPORATION (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 54 PHC HOLDINGS CORPORATION (JAPAN): SWOT ANALYSIS
FIGURE 55 CELL SIGNALING TECHNOLOGY INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 56 CELL SIGNALING TECHNOLOGY INC. (US): SWOT ANALYSIS
FIGURE 57 BIO SB INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 58 BIO SB INC. (US): SWOT ANALYSIS
FIGURE 59 MILTENYI BIOTECH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 60 MILTENYI BIOTECH (GERMANY): SWOT ANALYSIS
FIGURE 61 SAKURA FINETEK JAPAN CO., LTD. (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 62 SAKURA FINETEK JAPAN CO., LTD. (JAPAN): SWOT ANALYSIS
FIGURE 63 ENZO BIOCHEM, INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 64 ENZO BIOCHEM, INC. (US): SWOT ANALYSIS
FIGURE 65 ORIGENE TECHNOLOGIES INC. (US). : FINANCIAL OVERVIEW SNAPSHOT
FIGURE 66 ORIGENE TECHNOLOGIES INC. (US).: SWOT ANALYSIS